COVID Vaccine Developments; Long-Term Facility Study; Cannabidiol; New Depression Treatment; Peanut Allergy Rejection

<p><span style="font-weight: 400;">This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.</span></p>